{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:09:19Z","timestamp":1793236159793,"version":"4.5.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,24]],"date-time":"2017-10-24T00:00:00Z","timestamp":1508803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,10,24]],"date-time":"2017-10-24T00:00:00Z","timestamp":1508803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Signal transducer and activator of transcription 3 (STAT3) is phosphorylated by various kinases, several of which have been implicated in aberrant fibroblast activation in fibrotic diseases including systemic sclerosis (SSc). Here we show that profibrotic signals converge on STAT3 and that STAT3 may be an important molecular checkpoint for tissue fibrosis. STAT3 signaling is hyperactivated in SSc in a TGF\u03b2-dependent manner. Expression profiling and functional studies in vitro and in vivo demonstrate that STAT3 activation is mediated by the combined action of JAK, SRC, c-ABL, and JNK kinases. STAT3-deficient fibroblasts are less sensitive to the pro-fibrotic effects of TGF\u03b2. Fibroblast-specific knockout of STAT3, or its pharmacological inhibition, ameliorate skin fibrosis in experimental mouse models. STAT3 thus integrates several profibrotic signals and might be a core mediator of fibrosis. Considering that several STAT3 inhibitors are currently tested in clinical trials, STAT3 might be a candidate for molecular targeted therapies of SSc.<\/jats:p>","DOI":"10.1038\/s41467-017-01236-6","type":"journal-article","created":{"date-parts":[[2017,10,18]],"date-time":"2017-10-18T17:20:31Z","timestamp":1508347231000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":339,"title":["Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis"],"prefix":"10.1038","volume":"8","author":[{"given":"Debomita","family":"Chakraborty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbora","family":"\u0160umov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Mallano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfiya","family":"Distler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Ludolph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymund E.","family":"Horch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kolja","family":"Gelse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Ramming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Distler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladislav","family":"\u0160enolt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg H. W.","family":"Distler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,24]]},"reference":[{"key":"1236_CR1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/path.2277","volume":"214","author":"T Wynn","year":"2008","unstructured":"Wynn, T. Cellular and molecular mechanisms of fibrosis. J. Pathol. 214, 199\u2013210 (2008).","journal-title":"J. Pathol."},{"key":"1236_CR2","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMra0806188","volume":"360","author":"A Gabrielli","year":"2009","unstructured":"Gabrielli, A., Avvedimento, E. V. & Krieg, T. Scleroderma. N. Engl. J. Med. 360, 1989\u20132003 (2009).","journal-title":"N. Engl. J. Med."},{"key":"1236_CR3","doi-asserted-by":"crossref","DOI":"10.1172\/JCI31139","volume":"117","author":"J Varga","year":"2007","unstructured":"Varga, J. & Abraham, D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J. Clin. Invest. 117, 557 (2007).","journal-title":"J. Clin. Invest."},{"key":"1236_CR4","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrm3434","volume":"13","author":"J Massagu\u00e9","year":"2012","unstructured":"Massagu\u00e9, J. TGF\u03b2 signalling in context. Nat. Rev. Mol. Cell Biol. 13, 616\u2013630 (2012).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1236_CR5","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.v13.i22.3056","volume":"13","author":"F Verrecchia","year":"2007","unstructured":"Verrecchia, F. & Mauviel, A. Transforming growth factor-\u03b2 and fibrosis. World J. Gastroenterol. 13, 3056 (2007).","journal-title":"World J. Gastroenterol."},{"key":"1236_CR6","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1096\/fj.03-1273rev","volume":"18","author":"A Leask","year":"2004","unstructured":"Leask, A. & Abraham, D. J. TGF-\u03b2 signaling and the fibrotic response. FASEB J. 18, 816\u2013827 (2004).","journal-title":"FASEB J."},{"key":"1236_CR7","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/1523-1747.ep12313452","volume":"105","author":"K Kikuchi","year":"1995","unstructured":"Kikuchi, K. et al. Growth regulation in scleroderma fibroblasts: increased response to transforming growth factor-\u03b21. J. Investig. Dermatol. 105, 128\u2013132 (1995).","journal-title":"J. Investig. Dermatol."},{"key":"1236_CR8","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/art.22328","volume":"56","author":"S Sonnylal","year":"2007","unstructured":"Sonnylal, S. et al. Postnatal induction of transforming growth factor \u03b2 signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. Arthritis Rheumatol. 56, 334\u2013344 (2007).","journal-title":"Arthritis Rheumatol."},{"key":"1236_CR9","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1101\/gad.1350705","volume":"19","author":"J Massagu\u00e9","year":"2005","unstructured":"Massagu\u00e9, J., Seoane, J. & Wotton, D. Smad transcription factors. Genes Dev. 19, 2783\u20132810 (2005).","journal-title":"Genes Dev."},{"key":"1236_CR10","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature02006","volume":"425","author":"R Derynck","year":"2003","unstructured":"Derynck, R. & Zhang, Y. E. Smad-dependent and Smad-independent pathways in TGF-\u03b2 family signalling. Nature 425, 577\u2013584 (2003).","journal-title":"Nature"},{"key":"1236_CR11","volume":"19","author":"YE Zhang","year":"2009","unstructured":"Zhang, Y. E. Non-Smad pathways in TGF-\u03b2 signaling. Cell Res. 19, 128 (2009).","journal-title":"Cell Res."},{"key":"1236_CR12","doi-asserted-by":"crossref","DOI":"10.1172\/JCI200419603","volume":"114","author":"CE Daniels","year":"2004","unstructured":"Daniels, C. E. et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-\u03b2 and prevents bleomycin-mediated lung fibrosis. J. Clin. Investig. 114, 1308 (2004).","journal-title":"J. Clin. Investig."},{"key":"1236_CR13","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1096\/fj.07-105627","volume":"22","author":"A Akhmetshina","year":"2008","unstructured":"Akhmetshina, A. et al. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J. 22, 2214\u20132222 (2008).","journal-title":"FASEB J."},{"key":"1236_CR14","doi-asserted-by":"crossref","DOI":"10.1097\/BOR.0b013e32830e48e8","volume":"20","author":"J Varga","year":"2008","unstructured":"Varga, J. & Pasche, B. Anti-TGF-\u00df therapy in fibrosis: recent progress and implications for systemic sclerosis. Curr. Opin. Rheumatol. 20, 720 (2008).","journal-title":"Curr. Opin. Rheumatol."},{"key":"1236_CR15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1126\/science.8140422","volume":"264","author":"Z Zhong","year":"1994","unstructured":"Zhong, Z., Wen, Z. & Darnell, J. E. Jr Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264, 95\u201399 (1994).","journal-title":"Science"},{"key":"1236_CR16","doi-asserted-by":"crossref","DOI":"10.1038\/sj.onc.1206479","volume":"22","author":"L Song","year":"2003","unstructured":"Song, L., Turkson, J., Karras, J. G., Jove, R. & Haura, E. B. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 22, 4150 (2003).","journal-title":"Oncogene"},{"key":"1236_CR17","volume":"89","author":"Y Yan","year":"2016","unstructured":"Yan, Y. et al. Src inhibition blocks renal interstitial fibroblast activation and ameliorates renal fibrosis. Kidney Int. 89, 68 (2016).","journal-title":"Kidney Int."},{"key":"1236_CR18","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.bcp.2009.09.008","volume":"79","author":"J-H Kim","year":"2010","unstructured":"Kim, J.-H. et al. Jnk signaling pathway-mediated regulation of Stat3 activation is linked to the development of doxorubicin resistance in cancer cell lines. Biochem. Pharmacol. 79, 373\u2013380 (2010).","journal-title":"Biochem. Pharmacol."},{"key":"1236_CR19","doi-asserted-by":"crossref","DOI":"10.1038\/sj.onc.1204349","volume":"20","author":"R Garcia","year":"2001","unstructured":"Garcia, R. et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20, 2499 (2001).","journal-title":"Oncogene"},{"key":"1236_CR20","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/stem.1609","volume":"32","author":"G Huang","year":"2014","unstructured":"Huang, G., Yan, H., Ye, S., Tong, C. & Ying, Q. L. STAT3 phosphorylation at tyrosine 705 and serine 727 differentially regulates mouse ESC fates. Stem Cells 32, 1149\u20131160 (2014).","journal-title":"Stem Cells"},{"key":"1236_CR21","doi-asserted-by":"crossref","DOI":"10.1038\/nm1162","volume":"11","author":"S Sano","year":"2005","unstructured":"Sano, S. et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat. Med. 11, 43 (2005).","journal-title":"Nat. Med."},{"key":"1236_CR22","volume":"2","author":"R Fagard","year":"2013","unstructured":"Fagard, R., Metelev, V., Souissi, I. & Baran-Marszak, F. STAT3 inhibitors for cancer therapy: Have all roads been explored? JAKSTAT 2, e22882 (2013).","journal-title":"JAKSTAT"},{"key":"1236_CR23","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1021\/acschembio.5b00945","volume":"11","author":"SL Furtek","year":"2016","unstructured":"Furtek, S. L., Backos, D. S., Matheson, C. J. & Reigan, P. Strategies and approaches of targeting STAT3 for cancer treatment. ACS Chem. Biol. 11, 308\u2013318 (2016).","journal-title":"ACS Chem. Biol."},{"key":"1236_CR24","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1517\/13543780802565791","volume":"18","author":"P Yue","year":"2009","unstructured":"Yue, P. & Turkson, J. Targeting STAT3 in cancer: how successful are we? Expert Opin. Investig. Drugs 18, 45\u201356 (2009).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"1236_CR25","volume":"9","author":"H Yu","year":"2009","unstructured":"Yu, H., Pardoll, D. & Jove, R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9, 798 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"1236_CR26","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.2174\/15665240113139990076","volume":"13","author":"E Chen","year":"2013","unstructured":"Chen, E. et al. A novel role of the STAT3 pathway in brain inflammation-induced human neural progenitor cell differentiation. Curr. Mol. Med. 13, 1474\u20131484 (2013).","journal-title":"Curr. Mol. Med."},{"key":"1236_CR27","first-page":"122","volume":"31","author":"C Muangchant","year":"2012","unstructured":"Muangchant, C. & Pope, J. The significance of interleukin-6 and C-reactive protein in systemic sclerosis: a systematic literature review. Clin. Exp. Rheumatol. 31, 122\u2013134 (2012).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1236_CR28","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1101\/gad.1166904","volume":"18","author":"B Ohkawara","year":"2004","unstructured":"Ohkawara, B. et al. Role of the TAK1-NLK-STAT3 pathway in TGF-\u03b2-mediated mesoderm induction. Genes Dev. 18, 381\u2013386 (2004).","journal-title":"Genes Dev."},{"key":"1236_CR29","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nm.4082","volume":"22","author":"H Laklai","year":"2016","unstructured":"Laklai, H. et al. Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Nat. Med. 22, 497\u2013505 (2016).","journal-title":"Nat. Med."},{"key":"1236_CR30","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1158\/1078-0432.CCR-07-1176","volume":"14","author":"L Zhang","year":"2008","unstructured":"Zhang, L. et al. Effects of plasmid-based Stat3-specific short hairpin RNA and GRIM-19 on PC-3M tumor cell growth. Clin. Cancer Res. 14, 559\u2013568 (2008).","journal-title":"Clin. Cancer Res."},{"key":"1236_CR31","doi-asserted-by":"crossref","first-page":"7391","DOI":"10.1073\/pnas.0609757104","volume":"104","author":"K Siddiquee","year":"2007","unstructured":"Siddiquee, K. et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc. Natl Acad. Sci. USA 104, 7391\u20137396 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1236_CR32","doi-asserted-by":"crossref","first-page":"30708","DOI":"10.1074\/jbc.M113.478685","volume":"288","author":"Y Liu","year":"2013","unstructured":"Liu, Y. et al. Transforming growth factor-\u03b2 (TGF-\u03b2)-mediated connective tissue growth factor (CTGF) expression in hepatic stellate cells requires Stat3 signaling activation. J. Biol. Chem. 288, 30708\u201330719 (2013).","journal-title":"J. Biol. Chem."},{"key":"1236_CR33","doi-asserted-by":"crossref","first-page":"7954","DOI":"10.1158\/0008-5472.CAN-04-1013","volume":"64","author":"M Uhl","year":"2004","unstructured":"Uhl, M. et al. SD-208, a novel transforming growth factor \u03b2 receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res. 64, 7954\u20137961 (2004).","journal-title":"Cancer Res."},{"key":"1236_CR34","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1136\/annrheumdis-2011-200412","volume":"71","author":"N Reich","year":"2012","unstructured":"Reich, N. et al. Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis. Ann. Rheum. Dis. 71, 737\u2013745 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"1236_CR35","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1002\/art.23436","volume":"58","author":"C Skhirtladze","year":"2008","unstructured":"Skhirtladze, C. et al. Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. Arthritis Rheumatol. 58, 1475\u20131484 (2008).","journal-title":"Arthritis Rheumatol."},{"key":"1236_CR36","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1074\/jbc.M116.773085","volume":"292","author":"L-Y Tang","year":"2017","unstructured":"Tang, L.-Y. et al. Transforming growth factor-\u03b2 (TGF-\u03b2) directly activates the JAK1-STAT3 axis to induce hepatic fibrosis in coordination with the SMAD pathway. J. Biol. Chem. 292, 4302\u20134312 (2017).","journal-title":"J. Biol. Chem."},{"key":"1236_CR37","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1136\/annrheumdis-2016-210911","volume":"76","author":"Y Zhang","year":"2017","unstructured":"Zhang, Y. et al. JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment. Ann. Rheum. Dis. 76, 1467\u20131475 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"1236_CR38","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/ki.2010.154","volume":"78","author":"M Pang","year":"2010","unstructured":"Pang, M. et al. A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy. Kidney Int. 78, 257\u2013268 (2010).","journal-title":"Kidney Int."},{"key":"1236_CR39","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1073\/pnas.94.8.3801","volume":"94","author":"K Takeda","year":"1997","unstructured":"Takeda, K. et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc. Natl Acad. Sci. USA 94, 3801\u20133804 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1236_CR40","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/stem.170138","volume":"17","author":"S Akira","year":"1999","unstructured":"Akira, S. Functional roles of STAT family proteins: lessons from knockout mice. Stem Cells 17, 138\u2013146 (1999).","journal-title":"Stem Cells"},{"key":"1236_CR41","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1468-3083.2011.04206.x","volume":"26","author":"P Moinzadeh","year":"2012","unstructured":"Moinzadeh, P. et al. Biomarkers for skin involvement and fibrotic activity in scleroderma. J. Eur. Acad. Dermatol. Venereol. 26, 267\u2013276 (2012).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"1236_CR42","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2217\/bmm.09.79","volume":"4","author":"SV Castro","year":"2010","unstructured":"Castro, S. V. & Jimenez, S. A. Biomarkers in systemic sclerosis. Biomark. Med. 4, 133\u2013147 (2010).","journal-title":"Biomark. Med."},{"key":"1236_CR43","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/art.27220","volume":"62","author":"G Farina","year":"2010","unstructured":"Farina, G., Lafyatis, D., Lemaire, R. & Lafyatis, R. A four\u2010gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheumatology 62, 580\u2013588 (2010).","journal-title":"Arthritis Rheumatology"},{"key":"1236_CR44","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/1346-8138.13156","volume":"43","author":"M Hasegawa","year":"2016","unstructured":"Hasegawa, M. Biomarkers in systemic sclerosis: their potential to predict clinical courses. J. Dermatol. 43, 29\u201338 (2016).","journal-title":"J. Dermatol."},{"key":"1236_CR45","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/ni.2947","volume":"15","author":"N Schmitt","year":"2014","unstructured":"Schmitt, N. et al. The cytokine TGF-\u03b2 co-opts signaling via STAT3-STAT4 to promote the differentiation of human TFH cells. Nat. Immunol. 15, 856\u2013865 (2014).","journal-title":"Nat. Immunol."},{"key":"1236_CR46","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.bbadis.2014.07.025","volume":"1842","author":"M-Y Xu","year":"2014","unstructured":"Xu, M.-Y. et al. Stat3 signaling activation crosslinking of TGF-\u03b21 in hepatic stellate cell exacerbates liver injury and fibrosis. Biochim. Biophys. Acta 1842, 2237\u20132245 (2014).","journal-title":"Biochim. Biophys. Acta"},{"key":"1236_CR47","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1126\/science.1172702","volume":"326","author":"A Chaudhry","year":"2009","unstructured":"Chaudhry, A. et al. CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. Science 326, 986\u2013991 (2009).","journal-title":"Science"},{"key":"1236_CR48","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/toxsci\/kfs199","volume":"129","author":"J Liu","year":"2012","unstructured":"Liu, J., Chen, B., Lu, Y., Guan, Y. & Chen, F. JNK-dependent Stat3 phosphorylation contributes to Akt activation in response to arsenic exposure. Toxicol. Sci. 129, 363\u2013371 (2012).","journal-title":"Toxicol. Sci."},{"key":"1236_CR49","volume":"26","author":"L Wang","year":"2007","unstructured":"Wang, L., Kurosaki, T. & Corey, S. Engagement of the B-cell antigen receptor activates STAT through Lyn in a Jak-independent pathway. Oncogene 26, 2851 (2007).","journal-title":"Oncogene"},{"key":"1236_CR50","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1002\/art.34500","volume":"64","author":"C Dees","year":"2012","unstructured":"Dees, C. et al. JAK\u20102 as a novel mediator of the profibrotic effects of transforming growth factor \u03b2 in systemic sclerosis. Arthritis Rheumatol. 64, 3006\u20133015 (2012).","journal-title":"Arthritis Rheumatol."},{"key":"1236_CR51","volume":"35","author":"G Wang","year":"2016","unstructured":"Wang, G. et al. STAT3 selectively interacts with Smad3 to antagonize TGF-\u03b2 signaling. Oncogene 35, 4388 (2016).","journal-title":"Oncogene"},{"key":"1236_CR52","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1002\/art.27647","volume":"62","author":"C Beyer","year":"2010","unstructured":"Beyer, C., Schett, G., Distler, O. & Distler, J. H. Animal models of systemic sclerosis: prospects and limitations. Arthritis Rheumatol. 62, 2831\u20132844 (2010).","journal-title":"Arthritis Rheumatol."},{"key":"1236_CR53","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1038\/jid.2013.182","volume":"133","author":"RM Andr\u00e9s","year":"2013","unstructured":"Andr\u00e9s, R. M., Montesinos, M. C., Naval\u00f3n, P., Pay\u00e1, M. & Terencio, M. C. NF-\u03baB and STAT3 inhibition as a therapeutic strategy in psoriasis: in vitro and in vivo effects of BTH. J. Investig. Dermatol. 133, 2362\u20132371 (2013).","journal-title":"J. Investig. Dermatol."},{"key":"1236_CR54","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/721608","volume":"2011","author":"TC Barnes","year":"2011","unstructured":"Barnes, T. C., Anderson, M. E. & Moots, R. J. The many faces of interleukin-6: the role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosis. Int. J. Rheumatol. 2011, 721608 (2011).","journal-title":"Int. J. Rheumatol."},{"key":"1236_CR55","doi-asserted-by":"crossref","first-page":"12929","DOI":"10.1073\/pnas.2134694100","volume":"100","author":"JJ Jacoby","year":"2003","unstructured":"Jacoby, J. J. et al. Cardiomyocyte-restricted knockout of STAT3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with advanced age. Proc. Natl Acad. Sci. USA 100, 12929\u201312934 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1236_CR56","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1093\/rheumatology\/keq275","volume":"49","author":"Y Shima","year":"2010","unstructured":"Shima, Y. et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology 49, 2408\u20132412 (2010).","journal-title":"Rheumatology"},{"key":"1236_CR57","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/05bed72c-c6f6-4685-a732-02c78e5f66c2","volume":"3","author":"A Milano","year":"2008","unstructured":"Milano, A. et al. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS ONE 3, e2696 (2008).","journal-title":"PLoS ONE"},{"key":"1236_CR58","volume":"10","author":"KA Mueller","year":"2015","unstructured":"Mueller, K. A. et al. Clinical and histopathological features of patients with systemic sclerosis undergoing endomyocardial biopsy. PLoS ONE 10, e0126707 (2015).","journal-title":"PLoS ONE"},{"key":"1236_CR59","volume":"8","author":"J Jin","year":"2014","unstructured":"Jin, J., Chou, C., Lima, M., Zhou, D. & Zhou, X. Systemic sclerosis is a complex disease associated mainly with immune regulatory and inflammatory genes. Open Rheumatol. J. 8, 29 (2014).","journal-title":"Open Rheumatol. J."},{"key":"1236_CR60","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1002\/acr.21668","volume":"64","author":"M Elhai","year":"2012","unstructured":"Elhai, M. et al. Ultrasonographic hand features in systemic sclerosis and correlates with clinical, biologic, and radiographic findings. Arthritis Care Res. 64, 1244\u20131249 (2012).","journal-title":"Arthritis Care Res."},{"key":"1236_CR61","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.4049\/jimmunol.1401779","volume":"194","author":"C Li","year":"2015","unstructured":"Li, C. et al. Noncanonical STAT3 activation regulates excess TGF-\u03b21 and collagen I expression in muscle of stricturing Crohn\u2019s disease. J. Immunol. 194, 3422\u20133431 (2015).","journal-title":"J. Immunol."},{"key":"1236_CR62","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/jid.2010.255","volume":"131","author":"K Miyoshi","year":"2011","unstructured":"Miyoshi, K. et al. Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA-21, a Stat3 inhibitor. J. Investig. Dermatol. 131, 108\u2013117 (2011).","journal-title":"J. Investig. Dermatol."},{"key":"1236_CR63","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F Hoogen","year":"2013","unstructured":"Hoogen, F. et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against rheumatism collaborative initiative. Arthritis Rheumatol. 65, 2737\u20132747 (2013).","journal-title":"Arthritis Rheumatol."},{"key":"1236_CR64","first-page":"1573","volume":"28","author":"EC LeROY","year":"2001","unstructured":"LeROY, E. C. & Medsger, T. A. Criteria for the classification of early systemic sclerosis. J. Rheumatol. 28, 1573\u20131576 (2001).","journal-title":"J. Rheumatol."},{"key":"1236_CR65","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/nm.3777","volume":"21","author":"K Palumbo-Zerr","year":"2015","unstructured":"Palumbo-Zerr, K. et al. Orphan nuclear receptor NR4A1 regulates transforming growth factor-[beta] signaling and fibrosis. Nat. Med. 21, 150\u2013158 (2015).","journal-title":"Nat. Med."},{"key":"1236_CR66","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms1734","volume":"3","author":"A Akhmetshina","year":"2012","unstructured":"Akhmetshina, A. et al. Activation of canonical Wnt signalling is required for TGF-\u03b2-mediated fibrosis. Nat. Commun. 3, 735 (2012).","journal-title":"Nat. Commun."},{"key":"1236_CR67","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-015-0659-5","volume":"17","author":"N Ruzehaji","year":"2015","unstructured":"Ruzehaji, N. et al. Combined effect of genetic background and gender in a mouse model of bleomycin-induced skin fibrosis. Arthritis Res. Ther. 17, 145 (2015).","journal-title":"Arthritis Res. Ther."}],"updated-by":[{"DOI":"10.1038\/s41467-021-27450-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T00:00:00Z","timestamp":1638921600000}}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-01236-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-01236-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-01236-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T17:30:27Z","timestamp":1719509427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-01236-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,24]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["1236"],"URL":"https:\/\/doi.org\/10.1038\/s41467-017-01236-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,24]]},"assertion":[{"value":"30 May 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41467-021-27450-x","URL":"https:\/\/doi.org\/10.1038\/s41467-021-27450-x","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Although none of the authors has any direct conflict of interest related to the use or development of STAT3 inhibitors, O.D. and J.H.W.D. are involved in the development of new targeted therapies for fibrotic diseases such as SSc. O.D. has consultancy relationships and\/or has received research funding from Actelion, Pfizer, Ergonex, BMS, Sanofi-Aventis, United BioSource Corporation, Roche\/Genentech, Medac, Biovitrium, Boehringer Ingelheim, Novartis, 4D Science, Active Biotech, Bayer, Sinoxa, Serodapharm, EpiPharm, GSK, Pharmacyclics, and Biogen. J.H.W.D. has consultancy relationships with Actelion, Active Biotech, Anamar, Bayer Pharma, Boehringer Ingelheim, Celgene, Galapagos, Inventiva, JB Therapeutics, Medac, Pfizer, RuiYi, and UCB. J.H.W.D. has received research funding from Anamar, Active Biotech, Array Biopharma, BMS, Bayer Pharma, Boehringer Ingelheim, Celgene, GSK, Novartis, Sanofi-Aventis, and UCB. J.H.W.D. is stock owner of 4D Science. The remaining authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1130"}}